| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7fc9f67a0e0226411fa85130997b0da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4246bdc2260c219e72ec61a1dc63cfaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5a6804421cfa3699a624d85fa0614cf |
| publicationDate |
2021-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021030156-A1 |
| titleOfInvention |
Compositions and methods for diagnosis and treatment of bladder cancer |
| abstract |
The present disclosure relates generally to, inter alia, therapeutic and diagnostic methods and compositions for treatment of bladder cancer. In particular, the disclosure relates to defining pre-treatment gene signatures that are predictive of response to anti-PD-Ll therapy and to the use of such gene signatures as biomarkers to identify individuals having or suspected of having bladder cancer who are most likely to respond to an anti-PD-Ll therapy. In some embodiments, various methods for the treatment of bladder cancer in individuals identified by the diagnostic methods disclosed herein are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113265467-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021224215-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022211620-A1 |
| priorityDate |
2019-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |